EHS
EHS

CREDENCE trial stopped early for favorable CKD findings with canagliflozin

The steering committee behind the phase 3 CREDENCE clinical trial, evaluating the efficacy and safety of the SGLT2 inhibitor canagliflozin vs. placebo for adults with type 2 diabetes and chronic kidney disease, announced an early stop of the trial based on the achievement of prespecified efficacy criteria, according to a press release from Janssen.
The decision is based on a recommendation from the study’s independent data monitoring committee that met to review the data during a planned interim analysis, according to Janssen. This recommendation was based on demonstration of efficacy
EHS
Back to top button